Safety of mycophenolate mofetil versus azathioprin in renal transplantation: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 5, Issue 5, 2005, Pages 365-374

  Wang, Kun Jie ^a   Zhang, Hai Tao ^b   Li, You Ping ^a,c   Lu, Yi Ping ^a   Wei, Qiang ^a   Li, Hong ^a   Yang, Yu Ru ^a  

^a SICHUAN UNIVERSITY   (China)

^b Third People's Hospital of Chengdu   (China)

^c Chinese Evidence Based Medicine/Cochrane Center   (China)

Author keywords

Adverse drug reaction; Azathioprine; Mycophenolate acid; Renal transplantation; Systematic review

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL PAIN; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DATA BASE; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; EMBASE; EVALUATION; FOLLOW UP; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MEDLINE; META ANALYSIS; MORBIDITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN CARCINOMA; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 20144383731     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation[J]. Am J Kidney Disease, 1999; 34(2): 296-303.
2. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil in cadaveric renal transplant recipients[J]. Transplantation, 2000; 69(5): 875-880.
3. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up[J]. Transplantation, 2001; 71(8): 1091-1097.
4. Johnson C, Ahsan N, Gonwa T, Hallorax P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J. Random trial of tacrolimus in combination with AZAthioprine or mycophenolate mofetil versus cyclosporine with mycophenolate mofetil after cadaveric kidney transplantation[J]. Transplantation, 2000; 69(5): 834-841.
5. Jirasiritham S, Sumethkul V, Mavichak V, Chalermsanyakorn P. The treatment of chronic rejection with mycophenolate mofetil versus AZAthioprine in kidney transplantation[J]. Transplant Proc, 2000; 32(7): 2040-2042.
6. Suhail SM, Vathsala A, Lou HX, Woo KT. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients[J]. Transplant Proc, 2000; 32(7): 1757-1758.
7. Mathew TH. A blinded, long-time, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: result at three years[J]. Transplantation, 1998; 65(11): 1450-1454.
8. Mendez R. FK506 and mycophenolate mofetil in renal transplant recipients: six-month result of a multicenter, randomized dose ranging trial[J]. Transplantation Proc, 1998; 30(4): 1287-1289.
9. The Mycophenolate mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection[J]. Transplantation, 1998; 65(2): 235-241.
10. Neylan JE. Immunosupppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients[J]. Transplantation, 1997; 64(9): 1277-1282.
11. The U. S. Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year[J]. Transplant Proc, 1997; 29(1-2): 348-349.
12. The Tricontinental Mycophnolate Mofetil Rneal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation [J]. Transplantation, 1996; 61(7): 1029-1037.
13. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate in renal transplantation: 3-year results from the placebo-controlled trial[J]. Transplantation, 1999; 68(3): 391-396.
14. Solinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients[J]. Transplantation, 1995; 60(3): 225-232.
15. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroid for prevention of acute rejection[J]. Lancet, 1995; 345(8 961): 1321-1325.
16. Ji YL, Yang YQ, Yang GB, Yu XQ, Jiang PZ, Shen QD, Wu PG, Zhu LY. The clinical investigation of mycophenolate mofetil for the prevention of acute rejection[J]. Acad J SUMS, 2001; 22(3): 215-217.
17. Huang LP, Yang SY, Wu XT, Chen ZB, Wang ZX, Wei X. Clinical observation on the early application of cellcept following cadaveric renal tansplantation[J]. Chin J Organ Transplant, 2000; 21 (5): 294-295.
18. Guo HB, Zhang YH. The use of mycophenolate mofetil in renal tansplantation[J]. China J New Drug, 1998; 7(6): 444-446.
19. Ling JY, Zhu Y, Sun FK. Combined use of MMF with low dosage of cyclosporine A in renal tansplantation[J]. Chin J Organ Transplant, 1998; 19(3): 175-176.
20. Wang QW, Ji SM, Chen JS, Yin LP, Xu B, Chen HP, Li LS. Prevention acute rejection of MMF in renal transplantation[J]. J Nephrol Dialy Transplant, 1998; 7(1): 34-37.
21. Giuseppe R, Mariadomenica L, Eliana G, Maria G, Borislav DD, Bogdan EI, Giulia G, Donato D, Maurizio S, Silvio S, Umberto V, Giuseppe S, Georges M, Stefano F, Paolo R, Vito S, Jean-Louis B, Norberto P, Piero R. Mycophenolate mofetil versus AZAthioprine for prevention of acute rejection in renal transplantation (MYSS): a andomised trial[J]. Lancet, 2004; 364(7): 503-512.
22. Sami S, Jos'e M, Manuel A, Jacques S, Jean-paul S, Bruno V. Short-term combination of mcophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients[J]. Transplantation, 2002; 74(4): 511-517.
23. Miladipour AH, Ghods AJ, Nejadgashti H. Effect of mcophenolate mofetil on the prevention of acute renal allograft rejecrion[J]. Transplantation Proceedings, 2002; 34: 2089-2090.
24. Metcalfe MS, Jain S, Waller JR, Saunders RN, Bicknell GR, Nicholson ML. A randomized trial of mycophenolate mofetil versus AZAthioprine as calcineurin inhibitor sparing agents in the treatment of chronic allograft nephropathy[J]. Transplantation Proceedings, 2002; 34: 1812-1814.
25. Zhang HT, Wang KJ, Li YP, Gao L, Liu J, Cai YJ. Systematic review of clinical research literatures about comparison mycophenolate acid and AZAthioprine after renal transplantation[J]. Chin J of EBM, 2004; 4(2): 79-91.
26. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection[J]. Transplantation, 1997; 63(1): 39-47.
27. Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation[J]. Q J Med, 2000; 93(3): 15-20.
28. Smak Gregoor PJ, Hesse CJ, van Gelder T. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients [J]. Transplant Proc, 1998; 30(423): 1192-1193.
29. Van Gelder T, Hilbrands LB, Vanrenterghem Y. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation[J]. Transplantation, 1999; 68(563): 261-266.
30. Shaw LM, Sollinger HW, Halloran P. Mycophenolate mofetil: a report of the consensus panel[J]. Ther Drug Monit, 1995; 17(43): 690-699.
31. Pillans PI, Rigby RJ, Kubler P. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients[J]. Clin Biochem, 2001; 34(43): 77-81.